Pimicotinib

Phase 2Small molecule

AAbbisko Therapeutics Co, Ltd

Pimicotinib is one of 36 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

Tenosynovial Giant Cell TumorRecruiting

Pancreatic CancerPhase 2

Active, not recruiting

Tenosynovial Giant Cell TumorPhase 2

Recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Byetta

1 3

Pimicotinib

AAbbisko Therapeutics Co, Ltd

Phase 2

1 4

ABI-007

Bristol-Myers Squibb

Preclinical

2 5

Sulfonylureas

Eli Lilly

Preclinical

1 6

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Chemotherapy Agents

Takeda

Preclinical

1 9

Meglitinides

Sanofi

Preclinical

1 10

Thiazolidinediones

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Pancreatic Cancer

NCT06111274

Q4 2029

Phase 2Recruiting

Tenosynovial Giant Cell Tumor

NCT07499362

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Recruiting·AAbbisko Therapeutics Co, Ltd·Phase 2·NCT06111274·82 enrolled

AIN1 trial

A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT07210996·20 enrolled

Metformin1 trial

A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06779253·39 enrolled

Moderate Hepatic Impairment1 trial

The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06562946·24 enrolled

Tenosynovial Giant Cell Tumor1 trial

Phase 2, Single-arm Study to Investigate the Tolerability, Pharmacokinetics, Efficacy, and Safety of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07499362·20 enrolled

1 more indication

Unspecified3 trials

A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06694948·26 enrolled

A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects

Completed·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT07126249·38 enrolled

A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects

Active, not recruiting·AAbbisko Therapeutics Co, Ltd·Phase 1·NCT06884072·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Pimicotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pimicotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pimicotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abbisko Therapeutics Co, Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAbbisko Therapeutics Co, Ltd

Pimicotinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Trials by Indication[1]

Pancreatic Cancer1 trial

AIN1 trial

Metformin1 trial

Moderate Hepatic Impairment1 trial

Tenosynovial Giant Cell Tumor1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News